Biopharma puts €45m into Blanch expansion

by Gazette Reporter
0 comment

Yet another pharmaceutical company is investing in Blanchardstown with Mallinckrodt plc announcing a €45m investment to expand its operations at College Business and Technology Park.
On Wednesday, May 20 the US biopharma specialists announced the construction of a new state-of-the-art manufacturing facility and office building which will provide 300 jobs during the two-year construction phase and 45 skilled full-time positions once the construction is completed.
This follows on from the announcement last week that Alexion Pharmaceuticals will invest €450m in an expansion of its operations in Mulhuddart which will create 200 jobs.
Bristol Myers Squibb also announced a €900m investment in Mulhuddart in November which will create 350 jobs.
An Tanaiste, Joan Burton, joined the company at the announcement event, as well as US ambassador to Ireland Kevin O’Malley.
Speaking at the announcement the Tanaiste said she was delighted that Mallinckrodt Pharmaceuticals has chosen to make this major new investment in Dublin.
“The pharmaceutical industry is a key contributor to Ireland’s economy and to Ireland’s growing international reputation as a medical innovation hub,” she said, adding that the announcement represented a significant development, both for the wider Dublin region and for Ireland Inc.
“Mallinckrodt has had a strong and valued presence in Ireland for over 20 years and these plans for this new site support our drive for job creation,” she said.
Mark Trudeau, chief executive officer and president of Mallinckrodt, said the company was proud to have had a significant presence in Ireland for over two decades, and this investment marked an important step for the company.
“Our Irish workforce has served as a tremendous asset to our global operations to date,” he said.
Welcoming the investment, Dr David Keenan, managing director, Mallinckrodt Pharmaceuticals, Ireland, said: “We are pleased to establish this new manufacturing operation on Irish soil and to strengthen Ireland’s pharmaceutical credentials in the process.”

Related Articles